RER for factors that were found to correlate independently with survival in multivariate analysis
| Factor . | Level . | RER . | 95% CI . | P . |
|---|---|---|---|---|
| Conventional therapy | ||||
| ISS stage (reference stage I) | Stage II | 1.26 | 1.12-1.41 | < .001 |
| ISS stage (reference stage I) | Stage III | 1.53 | 1.34-1.74 | |
| Performance status | 2+ vs 0-1 | 1.31 | 1.20-1.43 | < .001 |
| Durie-Salmon stage | III vs I or II | 1.24 | 1.14-1.36 | < .001 |
| Platelets | < 130 × 109/L vs ≥ 130 × 109/L | 1.38 | 1.21-1.56 | < .001 |
| Bone marrow plasma cell | ≥ 33% vs < 33% | 1.23 | 1.12-1.34 | < .001 |
| Age | 50+ y vs < 50 y | 1.24 | 1.08-1.41 | .001 |
| Hemoglobin | < 100 vs ≥ 100 g/L | 1.14 | 1.04-1.25 | .006 |
| IgA isotype | Present vs absent | 1.20 | 1.06-1.36 | < .001 |
| Creatinine | ≥ 176.8 μM vs < 176.8 μM | 1.20 | 1.36-1.07 | .003 |
| Serum M protein | Measurable vs not measurable | 0.79 | 0.68-0.92 | .002 |
| High-dose therapy | ||||
| ISS stage (reference stage I) | Stage II | 1.56 | 1.23-1.97 | < .001 |
| ISS stage (reference stage I) | Stage III | 2.00 | 0.52-2.63 | |
| Platelets | < 130 × 109/L vs > 130 × 109/L | 1.72 | 1.35-2.21 | < .001 |
| Durie-Salmon stage | III vs I or II | 1.32 | 1.08-1.61 | .007 |
| IgA isotype | Present vs absent | 1.31 | 1.07-1.60 | .008 |
| Creatinine | ≥ 176.8 μM vs < 176.8 μM | 1.38 | 1.06-1.79 | .015 |
| Age* | 50+ y vs < 50 y | 1.17 | 0.95-1.43 | .122 |
| Factor . | Level . | RER . | 95% CI . | P . |
|---|---|---|---|---|
| Conventional therapy | ||||
| ISS stage (reference stage I) | Stage II | 1.26 | 1.12-1.41 | < .001 |
| ISS stage (reference stage I) | Stage III | 1.53 | 1.34-1.74 | |
| Performance status | 2+ vs 0-1 | 1.31 | 1.20-1.43 | < .001 |
| Durie-Salmon stage | III vs I or II | 1.24 | 1.14-1.36 | < .001 |
| Platelets | < 130 × 109/L vs ≥ 130 × 109/L | 1.38 | 1.21-1.56 | < .001 |
| Bone marrow plasma cell | ≥ 33% vs < 33% | 1.23 | 1.12-1.34 | < .001 |
| Age | 50+ y vs < 50 y | 1.24 | 1.08-1.41 | .001 |
| Hemoglobin | < 100 vs ≥ 100 g/L | 1.14 | 1.04-1.25 | .006 |
| IgA isotype | Present vs absent | 1.20 | 1.06-1.36 | < .001 |
| Creatinine | ≥ 176.8 μM vs < 176.8 μM | 1.20 | 1.36-1.07 | .003 |
| Serum M protein | Measurable vs not measurable | 0.79 | 0.68-0.92 | .002 |
| High-dose therapy | ||||
| ISS stage (reference stage I) | Stage II | 1.56 | 1.23-1.97 | < .001 |
| ISS stage (reference stage I) | Stage III | 2.00 | 0.52-2.63 | |
| Platelets | < 130 × 109/L vs > 130 × 109/L | 1.72 | 1.35-2.21 | < .001 |
| Durie-Salmon stage | III vs I or II | 1.32 | 1.08-1.61 | .007 |
| IgA isotype | Present vs absent | 1.31 | 1.07-1.60 | .008 |
| Creatinine | ≥ 176.8 μM vs < 176.8 μM | 1.38 | 1.06-1.79 | .015 |
| Age* | 50+ y vs < 50 y | 1.17 | 0.95-1.43 | .122 |
Patients treated with conventional chemotherapy: n = 3484 with nonmissing values on all factors, 45% of 7765 patients; patients treated with high-dose therapy: n = 1654 patients with nonmissing values for all factors, 59% of 2784 patients.
Not significant, but included for comparison.